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Purpose: The evaluation of long-term visual outcome after the use of bevacizumab for the 
management of multilevel hemorrhage due to retinal arterial macroaneurysm (MA).
Case report: A 71-year-old hypertensive female presented with sudden reduction of visual 
acuity in her left eye (OS). Fundoscopy revealed an arterial macroaneurysm with preretinal and 
subretinal hemorrhage in the eye. Due to significant macular involvement, the patient received 
two intravitreal injections of bevacizumab within 2 months.
Results: Significant visual and anatomical recovery was observed 2 months later, which was 
confirmed by fluorescein angiography. At the end of a follow-up period (39 months) visual 
acuity and visual field were at normal levels.
Conclusion: Retinal MA is a relatively rare condition. Anti-vascular endothelial growth factor 
therapy appears a safe and effective treatment option for selected symptomatic individuals that 
may offer faster visual rehabilitation. Herein we report, for the first time, a 39-month follow-up 
of a retinal MA treated with anti-vascular endothelial growth factor therapy.
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Introduction
Retinal arterial macroaneurysms (MA) are localized fusiform or saccular vascular 
dilations occurring within the first three orders of bifurcation.1 Although most MA 
cases are usually quiescent and do not require intervention, others may lead to 
complications such as macular edema, retinal exudation, and multilevel retinal or 
intravitreal hemorrhage.2
Several therapeutic options have been proposed with varied visual outcome.1 Both 
bevacizumab and ranibizumab have been recently employed but with relatively limited 
follow-up.3–5 This is the first report of the use of anti-vascular endothelial growth 
factor (VEGF) agents specifically for MA therapy with sufficient long-term follow-up 
demonstrating significant functional and anatomical recovery.
Case report
A 71-year-old female was referred to the authors’ unit with sudden reduction of visual 
acuity in her left eye (OS). Her past medical history included systemic hypertension 
and a successful surgical repair of a middle cerebral artery aneurysm 10 years ago. 
Best-corrected visual acuity was 0.8 in the right eye and 0.3 in the left. Anterior 
segment examination was unremarkable, revealing only mild bilateral nuclear 
lens opacities. Intraocular pressure was within normal limits in both eyes. Dilated Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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fundoscopy showed an arterial MA along the superior 
temporal vascular arcades, accompanied by pre- and 
subretinal hemorrhage OS (Figure 1A and B). Fluorescein 
angiography revealed early filling with late leakage of 
the MA and significant masking due to a hemorrhage 
involving the macula (Figure 1C and D). Complete medical 
work up did not identify any other pathology (eg, diabetes 
mellitus), except systemic arterial hypertension. Her blood 
biochemical analysis was normal.
In view of the marked reduction in vision OS and because 
of her medical history, the patient received an intravitreal 
injection of bevacizumab (1.25 mg). One month after 
the first injection, visual acuity had improved to 0.4 OS, 
whereas dilated fundoscopy showed a partial resolution 
of the   pre- and subretinal hemorrhage. Due to the rapid 
response to the anti-VEGF therapy and the improvement in 
visual acuity, a second bevacizumab injection (1.25 mg) was 
performed at this visit. Subsequently, 1 month later, visual 
acuity had improved to 0.5 OS and fundoscopy examination 
revealed further resolution of fundus hemorrhage. This 
was also confirmed with angiography (Figure 2A–D). Four 
months later, visual acuity had improved to 0.8 OS and 
fundoscopy exam showed an almost normal fundus with 
complete resolution of all hemorrhages. One year later, 
visual acuity remained stable at 0.8 OS and angiography 
revealed almost normal perfusion of the retina. At the final 
follow-up visit (39 months after diagnosis), vision remained 
at 0.8 OS and a final fluorescein angiogram confirmed the 
complete absorption of hemorrhages, with normal perfusion 
of the previously affected retina (Figure 3A–D).
Discussion
Retinal arterial MA is a relatively rare condition occurring in 
the course of hypertensive vascular disease, atherosclerosis, 
and retinal vein occlusion.1 It is usually associated with old 
age and has a female predominance (60%–100% of reported 
cases).1 As in the case discussed, previous reports have 
documented a correlation between retinal arterial MA and the 
occurrence of cerebral arterial aneurysms, which are also more 
common in hypertensive females over 50 years of age.1
The pathogenesis of retinal MA is currently unknown. 
As arterioles age, intimal collagen replaces smooth muscle 
fibers, and the arterial wall becomes less elastic. These 
vessels are thought to be more susceptible to dilation 
Figure 1 Color fundus photograph (A) and red-free photograph (B) of the left 
eye at baseline, showing multilevel hemorrhage due to a macroaneurysm. There is 
fluorescein filling of the macroaneurysm during the early phase (C) and mild leakage 
during late phase (D).
Figure 2 Two months later: color fundus photograph of the left eye (A) and red-
free photograph of the macroaneurysm (B) showing the fundus to be more normal, 
whereas early to midphase fluorescein angiogram (C) shows normal filling of the 
artery, and the later phase fluorescein angiogram (D) shows a substantial leakage.
Figure 3 Thirty-nine months later: color fundus photograph of the left eye (A); red-
free photograph (B); early (C) and late (D) phase of the fluorescein angiogram 
showing complete absorption of hemorrhage and resolution of the macroaneurysm 
leaving focal perivascular fibrosis.Clinical Ophthalmology
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from elevated hydrostatic pressure.1,6 This phenomenon is 
more evident in hypertensive patients, who also experi-
ence   elevated hydrostatic pressure, decreased autoregulation, 
and hyaline degeneration and are therefore especially at 
risk.1,6 Systemic hypertension has been implicated as a risk 
factor for exacerbation of several ocular ischemic disorders 
due to increased vascular permeability and intraocular 
neovascularisation, conditions that are primarily mediated by 
VEGF. Further, the increased mechanical stretch of the retinal 
endothelium, due to systemic hypertension, has been found 
to induce VEGF responses.7 This may also play a role in the 
formation of a MA; however, the precise pathogenetic cause 
of focal arterial wall weakness is not fully understood. In gen-
eral, it is agreed that a MA occurs at arteriovenous crossings 
where the vessels are in contact without an adventitial layer, 
resulting in an area with less structural support.1,6
Therapeutic options for managing a MA vary without 
clear guidelines yet available. In general, it is agreed that this 
is usually a benign condition, which may resolve spontane-
ously with bleeding, because hemorrhage tends to thrombose 
the aneurysms that subsequently may lead to its involution.1 
Thus, observation is thought to be sufficient in asymptomatic 
patients, where spontaneous involution is not unusual.6 For 
the same reason, symptomatic patients with a decrease in 
visual acuity due to vitreous or preretinal hemorrhage may 
be observed up to 6 months before any surgical interven-
tion is made.6 In contrast, laser photocoagulation may be 
selected for an exudative MA, or surgical options may be 
chosen to manage multilevel bleeding, when there is macular 
involvement. This approach, however, is limited by several 
associated complications.4
Intravitreal injection of VEGF inhibitors, such as ranibi-
zumab or bevacizumab, are more recent therapeutic alternatives, 
shown to reduce vascular permeability,   normalize central   retinal 
thickness and, consequently, lead to visual   improvement. 
Since the development of retinal MA is   associated with focal 
damage to arterial walls, leading to localized ischemia and 
VEGF upregulation, the use of anti-VEGF agents has been 
suggested as a means of achieving rapid resolution of the 
condition with a limited rate of complication.3–5
The patient discussed here presented with multilevel 
hemorrhage causing sudden reduction of visual acuity. 
  Subretinal hemorrhage is thought to be toxic to retinal 
  tissue, resulting in irreversible damage to photoreceptors and 
retinal-pigmented epithelial cells after 2 weeks.6 When MA 
is complicated by extensive multilayer bleeding involving 
the macula and threatening permanent loss of vision, VEGF 
injection may be selected to elicit faster absorption of sub-
retinal bleeding.3–5 This was the course of action in this 
case. Importantly, the case discussed here furnishes some 
long-term evidence with a follow-up of 39 months following 
the intravitreal injection of bevacizumab. Rapid and almost 
complete resolution of the hemorrhages and significant visual 
recovery was observed, suggesting a successful and stable 
  outcome. It is conceivable that besides macular edema the use of 
anti-VEGF may also be beneficial for multilevel   hemorrhages 
associated with a retinal MA. Further investigation is required 
to confirm the outcome of this case in a larger series of MA 
patients and to establish the optimal treatment strategy.
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